Condition: Head and Neck Squamous Cell Carcinoma · Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
This trial aims to evaluate whether the addition of anti-PD-1 antibody to adjuvant postoperative chemoradiotherapy could improve disease free survival in patients with high-risk locally advanced head and neck squamous cell carcinoma (HNSCC).
This description comes directly from the study's public registry record.
Jingbo Wang, Dr. · +861087787249 · wangjingbo201001@163.com
Always discuss trial participation with your own doctor first.
| National Cancer Cencer/Cancer hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06170710